The purpose of this study is to determine if the oral intake of the dietary supplement SAMe increases blood homocysteine levels in healthy human subjects.

S-adenosyl-L-methionine (SAMe or AdoMet) is a commonly used nutritional supplement available in the United States since 1999. SAMe is metabolized to homocysteine, a known cardiovascular risk factor. No study has determined the effect exogenous SAMe administration has on the long-term levels of homocysteine in humans. As a nutritional supplement, SAMe is not regulated by the Food and Drug Administration, despite being used to treat clinical diseases such as depression and osteoarthritis.

Inclusion criteria:

• Women and men age 18 - 65
• Able to understand and sign a consent form

Exclusion criteria:

• Smoking
• Pregnant or lactating
• Women actively trying to conceive
• Diagnosis of panic disorder or bipolar disorder